Navigation Links
Genelabs Technologies to Present at the BIO CEO & Investor Conference
Date:2/7/2008

REDWOOD CITY, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that its Chief Financial Officer Fred Driscoll will present a company update at the BIO CEO Investor Conference at the Waldorf Astoria Hotel Tuesday, February 12, 2008 at 2:00 pm E.T.

The presentation is scheduled to be webcast live and may be accessed by going to the Investor Information section of the Genelabs website at http://www.genelabs.com or through the following URL: http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=GNLB&item_id=17523 37 The presentation will also be available for replay after the presentation for a limited time.

About Genelabs Technologies

Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program. We also have late-stage products for hepatitis E virus and lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit http://www.genelabs.com.

Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.

Contact: Frederick W. Driscoll

Chief Financial Officer

Phone: 650-562-1424


'/>"/>
SOURCE Genelabs Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genelabs Technologies, Inc. Announces Resignation of President and CEO
2. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
3. Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions
4. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
5. Guava Technologies Celebrates Tenth Anniversary
6. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
7. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
8. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
11. Vestibular Technologies Is Awarded Contract by Major Group Purchasing Organization (GPO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, LLC, ... announced today that two new patents have been allowed by the USPTO on ... Band-LOK, said, “We continue to explore additional clinically-relevant designs for both the implants ...
(Date:9/18/2017)... , a growing leader in Electronic Trial Master file solutions ... research organization, Multidisciplinary Association for Psychedelic Studies (MAPS). ... MAPS Public Benefit Corporation selects ... ... for the treatment of Posttraumatic Stress Disorder (PTSD). MAPS also reached ...
(Date:9/15/2017)... San Diego, CA (PRWEB) , ... September 15, ... ... manufacturer Grolltex, has recently closed what it calls an ‘Internal Seed B’ round ... of the company’s stock and was completed using a ‘SAFE’ documentation structure at ...
(Date:9/14/2017)... Frederick, Maryland (PRWEB) , ... ... ... today, proudly announces the launch of its CliniControl™ (CC) product portfolio, clinically-relevant ... manufacturing, accelerating clinical translation of human Mesenchymal Stem/Stromal Cell (hMSC)-based therapies. The ...
Breaking Biology Technology:
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):